Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7083461rdf:typepubmed:Citationlld:pubmed
pubmed-article:7083461lifeskim:mentionsumls-concept:C0007121lld:lifeskim
pubmed-article:7083461lifeskim:mentionsumls-concept:C1265905lld:lifeskim
pubmed-article:7083461lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:7083461lifeskim:mentionsumls-concept:C1518422lld:lifeskim
pubmed-article:7083461pubmed:issue2-3lld:pubmed
pubmed-article:7083461pubmed:dateCreated1982-8-26lld:pubmed
pubmed-article:7083461pubmed:abstractTextThirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.lld:pubmed
pubmed-article:7083461pubmed:languageenglld:pubmed
pubmed-article:7083461pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083461pubmed:citationSubsetIMlld:pubmed
pubmed-article:7083461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083461pubmed:statusMEDLINElld:pubmed
pubmed-article:7083461pubmed:issn0344-5704lld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:VagoGGlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:BianchiCClld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:PiazzeAAlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:MorascaLLlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:CogoRRlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:MarsoniSSlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:CasaliWWlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:ScapaticciRRlld:pubmed
pubmed-article:7083461pubmed:authorpubmed-author:PisoniM BMBlld:pubmed
pubmed-article:7083461pubmed:issnTypePrintlld:pubmed
pubmed-article:7083461pubmed:volume7lld:pubmed
pubmed-article:7083461pubmed:ownerNLMlld:pubmed
pubmed-article:7083461pubmed:authorsCompleteYlld:pubmed
pubmed-article:7083461pubmed:pagination209-10lld:pubmed
pubmed-article:7083461pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:meshHeadingpubmed-meshheading:7083461-...lld:pubmed
pubmed-article:7083461pubmed:year1982lld:pubmed
pubmed-article:7083461pubmed:articleTitleVP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.lld:pubmed
pubmed-article:7083461pubmed:publicationTypeJournal Articlelld:pubmed